First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC).

被引：0

作者：

Gazzah, Anas

Cousin, Sophie

Boni, Valentina

Ricordel, Charles

Kim, Tae Min

Kim, Jin-Soo

Helissey, Carole

Gardeazabal, Itziar

Chadjaa, Mustapha

Allard, Aurore

Yoruk, Semra

Barlesi, Fabrice

机构：

[1] Gustave Roussy, Dept Drug Dev DITEP, Villejuif, France

[2] Inst Bergonie, Bordeaux, France

[3] START Madrid Ctr, Madrid, Spain

[4] CHU Rennes, Serv Pneumol, Rennes, France

[5] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[6] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea

[7] HIA Begin, Dept Med Oncol, Clin Res Unit, Paris, France

[8] Vall DHebron Inst Oncol, Barcelona, Spain

[9] Sanofi R&D, Oncol, Vitry Sur Seine, France

[10] Sanofi, Chilly Mazarin, France

[11] Sanofi, Istanbul, Turkey

[12] Aix Marseille Univ, INSERM, CNRS, CRCM,APHM,CEPCM CLIP2, Marseille, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9072

引用

页数：2